Eshelman Ventures

Eshelman Ventures is a venture capital firm specializing in private healthcare companies, emphasizing active involvement in growth and strategy. Founded by Fred Eshelman, the firm engages in various investment strategies, including angel investing, venture capital partnerships, and private equity, with a participatory but non-obstructive style. Eshelman Ventures is committed to supporting innovative healthcare solutions and transformative medicines.

The firm's portfolio includes companies such as Incyclix Bio, developing small molecule inhibitors of cyclin-dependent kinases for cancer treatment; Jupiter Bioventures, building breakthrough biotech companies; Cavalry, engineering targeted growth factors; Genesis, focusing on company formation and venture growth in transformative medicines; Pacegenix, transforming the future of arrhythmia therapeutics; and KOMO Biosciences, specializing in next-generation precision genome editing.

Fred Eshelman, the founder, previously served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI), which was sold to private equity interests. He also served as Founding Chairman and largest shareholder of Furiex Pharmaceuticals, which was sold to Forest Labs/Actavis in 2014. His career includes positions as senior vice president (development) and board member of the former Glaxo, Inc., as well as various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Eshelman has received numerous awards, including the Davie and Distinguished Service Awards from UNC and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy, as well as the NC Entrepreneur Hall of Fame Award and the NC Business Hall of Fame. He received his Doctor of Pharmacy from the University of Cincinnati and completed the OPM program at Harvard Business School.

Eshelman Ventures is located at 5815 Oleander Drive Ste 105, Wilmington, NC 28403. For inquiries, they can be contacted via email at nan@eshelmanventures.com or by phone at (910) 558-6885.